azacitidine has been researched along with bortezomib in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Giles, FJ | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ikeda, H; Ishitsuka, K; Kiziltepe, T; Ocio, EM; Okawa, Y; Pozzi, S; Raje, N; Shiraishi, N; Vallet, S; Yasui, H | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Khong, T; Spencer, A | 1 |
| de Lima, M; Koreth, J; Reddy, P | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H | 1 |
| Jia, ZQ; Rong, HQ; Su, W; Tao, J; Wei, YL; Wei, YT; Yu, CX | 1 |
| Dunleavy, K; Jiang, Z; Kuo, PY; Leshchenko, VV; Overbey, J; Parekh, S; Weniger, MA; Wiestner, A; Wilson, WH | 1 |
| Adomako, A; Aguirre-Ghiso, JA; Biran, N; Calvo, V; Chari, A; Moore, K; Osman, K; Paton, AW; Paton, JC; Schewe, DM | 1 |
| Cao, Y; Gu, WY; Lin, Y; Qiu, GQ; Wang, ZL; Wu, HQ; Wu, W; Xie, XB | 1 |
| Bobin, A; Frouin, E; Hainaut, E; Masson Regnault, M; Plume, MA; Sibaud, V | 1 |
| Chandran, NS; Koh, XQ; Ooi, XT; Sun, Y; Tan, CL | 1 |
| Albayrak, M; Falay, M; Han, U; Maral, S; Ozturk, HBA; Sahin, O | 1 |
3 review(s) available for azacitidine and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Emerging therapies in hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat | 2012 |
4 trial(s) available for azacitidine and bortezomib
| Article | Year |
|---|---|
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
15 other study(ies) available for azacitidine and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Multiple Myeloma; Pyrazines | 2007 |
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; G1 Phase; HSP90 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinases; Multiple Myeloma; Pyrazines; Pyridones; Pyrimidines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29 | 2014 |
[Effects of bortezomib combined with 5-azacytidine on the apoptosis of K562 cells and expression of SHIP mRNA].
Topics: Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Inositol Polyphosphate 5-Phosphatases; K562 Cells; Phosphoric Monoester Hydrolases; Pyrazines; RNA, Messenger | 2014 |
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bortezomib; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Recurrence | 2015 |
Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
Topics: Adult; Aged; Animals; Apoptosis; Azacitidine; Bortezomib; Cell Survival; Cyclin-Dependent Kinase 6; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; p21-Activated Kinases; Xenograft Model Antitumor Assays | 2015 |
Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerases | 2016 |
Spider-like injection site reaction after subcutaneous administration of haematological treatments.
Topics: Antineoplastic Agents; Azacitidine; Bortezomib; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Skin | 2020 |
A retrospective analysis of dermatological problems in haematology and oncology patients at a tertiary Singapore hospital.
Topics: Antibodies, Bispecific; Antineoplastic Agents; Azacitidine; Bortezomib; ErbB Receptors; Hematologic Diseases; Humans; Immunotherapy; Neoplasms; Pemetrexed; Pyrimidines; Retrospective Studies; Singapore; Skin Diseases; Tertiary Care Centers | 2020 |
Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arm; Azacitidine; Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Fatal Outcome; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Myeloma Proteins; Necrosis | 2021 |